8 recruiting, 6 completed, 2 active not recruiting, 2 no longer available. 6 Phase 2, 5 Phase 1, 4 Phase 3, 2 Early Phase 1, 1 Not applicable.
Follow Ga(III)-DOTATOC: new trials by email Literature Review of Ga(III)-DOTATOC trials Research Report on Ga(III)-DOTATOC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 10 | 2026-06-30 | 2026-06-05 |
| RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography - Recurrent Meningioma | Phase 1 / Phase 2 | Recruiting | Joshua Palmer | 30 | 2025-11-12 | 2026-08-13 |
| Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. Stereotactic Body Radiation Therapy, Lutetium Lu 177 Dotatate, Computed Tomography - Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm | Phase 1 | Recruiting | Emory University | 15 | 2025-10-14 | 2026-03-02 |
| Graft Failure and Consequences of Coronary Artery Bypass Graft Surgery Hybrid [18F]-GP1, [68Ga]-DOTATATE, [68Ga]-FAPI total-body positron emission tomography and coronary computed tomography coronary angiography - Coronary Artery Bypass, Graft Failure | Recruiting | University of Edinburgh | 70 | 2025-03-28 | 2026-04-20 | |
| Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer 68Ga-DOTATOC - Breast Cancer Metastatic | Phase 3 | Recruiting | University Hospital, Grenoble | 25 | 2025-01-06 | 2025-03-04 |
| Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors 68Ga-DOTATOC - Advanced Gastroenteropancreatic Neuroendocrine Tumor | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 69 | 2024-02-22 | 2026-06-12 |
| Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE - Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 35 | 2023-12-27 | 2026-10-14 |
| Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel PET/CT-enterography with 68Ga-DOTATOC - Small Bowel Neoplasia, Neuroendocrine (NE) Tumors | Not applicable | Recruiting | European Institute of Oncology | 18 | 2021-04-23 | 2025-01-14 |
| Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery Lutathera, Gallium 68 Dotatate, Computed Tomography (CT) - Gastroenteropancreatic Neuroendocrine Tumor | Phase 1 | Active not recruiting | Stanford University | 10 | 2021-03-17 | 2026-08-12 |
| Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging - Grade 1 Meningioma, Grade 2 Meningioma | Phase 2 | Recruiting | Mayo Clinic | 42 | 2020-04-14 | 2026-10-13 |
| An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors Computed Tomography, Gallium Ga 68-DOTATATE, Positron Emission Tomography - Ganglioneuroblastoma, Ganglioneuroma | Early Phase 1 | Active not recruiting | Mayo Clinic | 20 | 2019-09-23 | 2026-03-31 |
| Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas Computed Tomography, Gallium Ga 68-DOTATATE, Positron Emission Tomography - Meningioma | Phase 1 | Completed | M.D. Anderson Cancer Center | 13 | 2019-01-10 | 2023-09-01 |
| Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer CT (Computed Tomography), Gallium Ga 68-DOTATATE, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Completed | Emory University | 17 | 2018-02-22 | 2025-07-17 |
| Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor 90Y-DOTA-TOC, 68Ga-DOTA-TOC - Neuroendocrine Tumor | Early Phase 1 | Completed | Thomas Hope | 10 | 2017-07-01 | 2020-07-07 |
| Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan 68Ga-DOTATOC - Neuroendocrine Tumors | Phase 3 | Completed | Montefiore Medical Center | 11 | 2016-05-16 | 2023-05-09 |
| Gallium-68 DOTATOC for Management of Neuroendocrine Tumors Gallium-68 DOTATOC - Neuroendocrine Tumors | No longer available | Northwell Health | 2015-04-01 | 2016-11-08 | ||
| 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) 68Ga-DOTATOC PET - Neuroendocrine Tumors, Carcinoid Tumors | Phase 1 | Terminated | Lale Kostakoglu | 71 | 2014-12-01 | 2017-05-03 |
| Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT [68Ga]DOTATOC - Glioma | Phase 2 / Phase 3 | Completed | Turku University Hospital | 30 | 2011-10-01 | 2013-12-12 |
| 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) 68Ga DOTATATE - Carcinoid Cancer, Neuroendocrine Tumors | No longer available | Jonsson Comprehensive Cancer Center | 2020-07-27 |
Neuroendocrine Tumors (5) · Meningioma (3) · Carcinoid Tumor (2) · Gastro-enteropancreatic neuroendocrine tumor (2) · Prostatic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Medullary (1) · Cardiovascular Diseases (1) · Disease (1) · Ganglioneuroblastoma (1) · Ganglioneuroma (1) · Glioma (1) · Heart Diseases (1) · Neoplasms (1) · Neuroblastoma (1)
Emory University (2) · Mayo Clinic (2) · European Institute of Oncology (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Jonsson Comprehensive Cancer Center (1) · Joshua Palmer (1) · Lale Kostakoglu (1) · M.D. Anderson Cancer Center (1) · Montefiore Medical Center (1) · National Cancer Institute (NCI) (1) · Northwell Health (1) · OHSU Knight Cancer Institute (1) · Stanford University (1) · Thomas Hope (1) · Turku University Hospital (1)
United States (12) · China (1) · Finland (1) · France (1) · Italy (1) · United Kingdom (1)
Brendan C Visser, MD (1) · Charito Love, MD (1) · Heikki RI Minn, M.D., Ph.D. (1) · Jason M Johnson (1) · Johannes Czernin, MD (1) · John M Floberg (1) · Joshua D Palmer, MD (1) · Kenneth W. Merrell, MD (1) · Lale Kostakoglu, MD, MPH (1) · Mehmet Asim Bilen, MD (1) · Nadia Laack, MD (1) · Pretesh Patel, MD (1) · Rodney F Pommier (1)
PMID 24693229, PMID 25075022, PMID 25977882, PMID 28076709, PMID 28450563, PMID 28473600, PMID 29503845
P30CA138292 (1), UM1CA186691 (1)